Evidence map›Paper›PMID 38462559›Full record

ArticleJournal of clinical immunology2024

Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.

Dongling Shi, Jie Chen, Meng Zhao, Yuanjia Tang, Chen Zhao, Yinpeng Jin, Di Tian, Yixin Liao, Xuebi Wang, Wei Wang and 4 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Dongling Shi *Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jie Chen *Department of Infectious Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Meng Zhao *Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Yuanjia TangShanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
Chen ZhaoScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yinpeng JinLiver Disease Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Di TianScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yixin LiaoScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xuebi WangDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Wei WangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xiaohong FanDepartment of Respiratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhigang YiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. zgyi@fudan.edu.cn.
Xiaohua ChenDepartment of Infectious Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. chenxiaohua2000@163.com.
Yun LingDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. yun.ling@shphc.org.cn.
Shanghai Public Health Clinical Center · CNFudan University · CNRenji Hospital · CNShanghai Jiao Tong University · CNShanghai Sixth People's Hospital · CN

Funding

National Key Research and Development Project of China 2023YFC0872600Shanghai 2020 "Science and Technology Innovation Action Plan" Medical Innovation Research Special 20Z11900900Shanghai Pujiang Program 23PJD073the Shanghai Hospital Development Center Foundation SHDC22022201-SHDC12022121the Shanghai "Medical Garden Rising Star" Youth Medical Talent Training Funding Program SHWJRS (2021)-99the Sixth People's Hospital of Shanghai ynxg202214Three-year Action Plan (2023-2025) and Key Discipline Program on Public Health System Construction of Shanghai GWV1-11.2-XD30Three-year Action Plan (2023-2025) and Key Discipline Program on Public Health System Construction of Shanghai GWVI-11.1-15
6 · The paper itself

Abstract

objectiveWe sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2.

methodsType I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted.

resultsIn this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts.

conclusionThe presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population.

Indexed as

COVID-19Interferon Type IAgedAntibodies, NeutralizingAntiviral AgentsAutoantibodiesChinaHumansMalePrevalenceSARS-CoV-2Antibodies, NeutralizingAntiviral AgentsAutoantibodiesInterferon Type ICOVID-19IFN-α2IFN-ωNeutralizing antibodiesType I interferons

Identifiers

PMID38462559
PMCPMC10925575
OpenAlexW4392764644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.